Implementation and effectiveness of evriMED with short messages service (SMS) reminders and tailored feedback compared to standard care on adherence to treatment among tuberculosis patients in Kilimanjaro, Tanzania: proposal for a cluster randomized controlled trial
DiscussionIf the intervention shows a significant effect on adherence and the devices are accepted, accurate, and sustainable, the intervention can be scaled up within the National Tuberculosis Programmes.Trial registrationPan African Clinical Trials Registry,PACTR201811755733759. Registered on 8 November 2018. (Source: Trials)
Source: Trials - July 12, 2019 Category: Research Source Type: clinical trials

Lowering InterLeukin-1 Receptor Antagonist Concentrations After TB Treatment Onset
Condition:   Tuberculosis Intervention:   Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   Institut Pasteur, Cambodia;   Institut National de la Santé Et de la Recherche Médicale, France;   European Georges Pompidou Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 11, 2019 Category: Research Source Type: clinical trials

Do mobile phone-based reminders and conditional financial transfers improve the timeliness of childhood vaccinations in Tanzania? Study protocol for a quasi-randomized controlled trial
This study evaluates the efficacy of mobile phone-based (mHealth) reminders and incentives for improving vaccination timeliness in the first year of life.MethodsThe study, conducted in Mtwara Region in Tanzania, includes 400 late-stage pregnant women enrolled from rural and urban health facilities and surrounding communities. The primary outcome is timeliness of vaccinations among their children at 6, 10, and 14  weeks after birth. Timeliness is defined as vaccination receipt within 28 days after the vaccination due date. The quasi-randomized controlled trial includes three arms: (1) standard of care (no remi...
Source: Trials - July 4, 2019 Category: Research Source Type: clinical trials

Innovation in Tuberculosis
Condition:   Tuberculosis Intervention:   Diagnostic Test: Immunologic, molecular, metabolomic and radiolologic diagnostic Sponsors:   Fundació Institut Germans Trias i Pujol;   Consorcio Centro de Investigación Biomédica en Red, M.P.;   Umeå University;   North-Western State Medical University named after I.I.Mechnikov;   INSTITUTUL DE FTIZIOPNEUMOLOGIE CHIRIL DRAGANIUC;   ODESA SIGNIFICANT DISEASES CENTE R;   Vinnitsa National Medical University;   SERVICIOS CLI...
Source: ClinicalTrials.gov - July 1, 2019 Category: Research Source Type: clinical trials

Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
Conditions:   HIV Infections;   Tuberculosis;   Candidiasis, Esophageal;   Cryptococcosis;   Leishmaniasis;   Toxoplasmosis Intervention:   Other: CD4 cell count Sponsor:   Singh, Ranjan Kumar, M.D. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 20, 2019 Category: Research Source Type: clinical trials

2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB: a 3-arm Randomized Trial.
Condition:   Latent Tuberculosis Interventions:   Drug: Rifampin double dose;   Drug: Rifampin triple dose;   Drug: Rifampin standard dose Sponsors:   McGill University;   Canadian Institutes of Health Research (CIHR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2019 Category: Research Source Type: clinical trials

2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB.
Condition:   Latent Tuberculosis Interventions:   Drug: Rifampin double dose;   Drug: Rifampin triple dose;   Drug: Rifampin standard dose Sponsors:   McGill University;   Canadian Institutes of Health Research (CIHR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 18, 2019 Category: Research Source Type: clinical trials